Indian Pharma at an Inflection Point: Key Takeaways from FE Pharma Summit 2026

The Indian pharmaceutical industry is shedding its "global back-office" skin to emerge as a high-stakes innovation hub. At the 3rd edition of the FE Pharma Summit & Awards 2026, industry captains, policymakers and investors reached a singular consensus: the USD 60-billion sector has hit an inflexion point where quality and value-led growth must now supersede the volume-driven models of the past.

The Shift from Volume to Value

Opening the summit, Roshun Povaiah, Editor, FE Digital, highlighted the sector's decisive pivot. While India has long been the "pharmacy of the world," the narrative is shifting toward high-value therapeutic segments. "The focus is moving rapidly toward oncology, cardiology, and diabetes care," Povaiah noted, adding that digital acceleration and targeted policy interventions are finally providing the tailwinds needed for this transition.

However, this shift requires more than just intent; it requires capital and patience. Abhishek Yadav, Managing Director at Quadria Capital, pointed to a glaring structural gap: India’s underrepresentation in the biologics and biotech space. While the US and China have institutionalised advanced therapeutics, India remains in a "catch-up" phase regarding research infrastructure and specialised talent.

"The single most critical enabler for long-term capital is predictability," Yadav emphasised. "To attract the patient capital biotech demands, we need regulatory visibility that spans a 5-to-10-year horizon."

The Domestic Growth Story

The summit also spotlighted a strategic rebalancing of portfolios. Sanjay Kumar, President & Chief Strategy Officer at Granules India, observed a marked shift in investor sentiment favouring companies with a robust domestic footprint.

"Strengthening the domestic base is no longer just a responsibility; it’s a commercially prudent strategy," Kumar said. Yet, he was quick to defend the "generics" label often dismissed as a commodity. He argued that the Indian generics industry remains the world’s most effective tool in easing fiscal pressures on global healthcare systems, a feat of engineering and scale that "deserves greater recognition."

Embedding Quality in the DNA

As the industry scales, the shadow of regulatory scrutiny looms large. Umesh Kale, Chief Quality Officer at Strides Pharma Science Ltd, cautioned against "compliance by fear." According to Kale, treating quality as a mere checklist is a short-term fix that compromises long-term credibility. The goal, he argued, must be embedding quality into the "organisational DNA," starting from the shop-floor controls and extending to the final manufacturing processes.

The Road to 2030: AI and Biopharma

In a forward-looking fireside chat, Sushil Suri, CMD of Morepen Laboratories Ltd, described the current era as a "brick-by-brick transformation." He highlighted how the integration of Artificial Intelligence is already compressing years of drug discovery research into weeks.

For Mr. Suri and many others at the summit, the message was clear: India’s pharma story is moving beyond the "low-cost provider" tag. The next chapter will be written by those who can successfully integrate into global value chains as strategic partners, leveraging biotech innovation and diagnostics to shape the future of global healthcare.